CRISPR Therapeutics
CRSP
170 hedge funds and large institutions have $929M invested in CRISPR Therapeutics in 2019 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 23 closing their positions.
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
47% more capital invested
Capital invested by funds: $631M → $929M (+$298M)
16% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 38
10% more funds holding
Funds holding: 155 → 170 (+15)
7.11% more ownership
Funds ownership: 42.63% → 49.75% (+7.1%)
35% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $21.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$57.7M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$28M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$27.7M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$24.1M |
| 5 |
VVM
Versant Venture Management
San Francisco,
California
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$18.2M |
| 2 |
Two Sigma Investments
New York
|
-$15M |
| 3 |
NLVP
New Leaf Venture Partners
New York
|
-$12.7M |
| 4 |
Two Sigma Advisers
New York
|
-$8.08M |
| 5 |
AC
Armistice Capital
New York
|
-$3.18M |
CRSP Hedge Fund Activity: Q1 2019 in Review
170 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2019, worth a combined $929M — up 47% from $631M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CRSP positions and 23 closed out — a net gain of 16 holders — while 44 added to existing stakes and 38 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $57.7M. The largest seller was Farallon Capital Management, cutting an estimated $18.2M.
- 170 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2019, up from 155 in Q4 2018.
- Funds reported $929M of CRISPR Therapeutics stock for Q1 2019, up 47% quarter-over-quarter.
- 39 funds opened new CRISPR Therapeutics positions in Q1 2019 and 23 closed out, a net change of +16 holders.
- The largest CRISPR Therapeutics buyer in Q1 2019 was EcoR1 Capital, an estimated $57.7M added.
- The largest CRISPR Therapeutics seller in Q1 2019 was Farallon Capital Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q1 2019.